Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 110, Issue 1, 2000, Pages 29-40

  Estlin, E J ^a   Lowis, S P ^a   Hall, A G ^b  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Antimetabolites; Childhood ALL; Optimization; Pharmacology

Indexed keywords

ANTIMETABOLITE; CYTARABINE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; TENIPOSIDE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; BOLUS INJECTION; CELL LEVEL; CEREBROSPINAL FLUID; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; REVIEW;

6-MERCAPTOPURINE; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; METHOTREXATE; TENIPOSIDE; THIOGUANINE;

EID: 0033880877     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02028.x     Document Type: Review

References (99)

1. New treatment schedule with improved survival in childhood leukaemia
2. Intrathecal 6-mercaptopurine: Preclinical pharmacology, phase I/II trial, and pharmacokinetic study
3. The cytotoxicity of thioguanine versus mercaptopurine in acute lymphoblastic leukaemia
4. Antifolates
5. Biochemical pharmacology of high dose 1-β-D-arabinofuranosylcytosine in childhood acute leukaemia
6. Pharmacology studies of 1-β-D-arabinofuranosylcytosine in pediatric patients with leukaemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug
7. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukaemia
8. Reduced folate carrier expression in acute lymphoblastic leukaemia, a mechanism for ploidy but not lineage differences in methotrexate accumulation
9. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in non-toxic patients after lumbar injection
10. Phase II study of VM-26 in acute leukaemia, neuroblastoma, and other refractory childhood malignancies: A report form the Children's Cancer Study Group
11. 42-Hour methotrexate infusions as relapse therapy for childhood malignancies
12. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukaemia
13. 2 in children with acute lymphoblastic leukaemia
14. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphoblastic leukaemia: A Pediatric Oncology group Study
15. VP16-213 (Etoposide). A critical review of its activity
16. Cytidine analogues
17. Phase II study of VP-16-123 in childhood malignant disease: A Children's Cancer Study Group Report
18. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X
19. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180)
20. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukaemia
21. 9/l
22. Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukaemic T-lymphocytes
23. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside
24. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia
25. Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukaemia: A follow up report
26. Pharmacokinetics of HD-MTX in infants, children and adolescents with non-B acute lymphoblastic leukaemia
27. Topoisomerase expression in cancer cells and clinical samples
28. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukaemia and refractory lymphoma: Clinical response and pharmacology
29. Etoposide-induced DNA cleavage in human leukaemia cells
30. The purine path to chemotherapy
31. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukaemia receiving 6-thioguanine versus 6-mercaptopurine
32. Pharmacokinetics of teniposide (VM26) and etoposide (VP16-23) in children with cancer
33. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia
34. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukaemia
35. Individualised doses of chemotherapy as a strategy to improve response for acute lymphocytic leukaemia
36. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia
37. The role of DNA mismatch repair in drug resistance
38. Studies of sequential and combination antimetabolite therapy in acute leukaemia: 6-Mercaptopurine and methotrexate
39. The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukaemia: A model for evaluation of other potentially useful therapy
40. Persistence of circulating blasts after one week of multi-agent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukaemia
41. Differences in folylpolyglutamyl synthase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukaemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamation and cytotoxicity
42. Decreased polyglutamation of methotrexate acute lymphoblastic leukaemia blasts in adults compared to children with this disease
43. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphoblastic leukaemia and is associated with decreased reduced folate carrier expression
44. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia
45. Purine antimetabolites
46. Consolidation therapy with antimetabolite-based therapy in standard risk acute lymphoblastic leukaemia of childhood: A Pediatric Oncology group Study
47. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukaemia: The Children's Cancer Group experience
48. Differences in the intracellular pharmacokinetics of cytosine arabinoside (Ara-C) between circulating leukaemic blasts and normal mononuclear blood cells
49. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine
50. Cytosine arabinoside. Results of a co-operative study in acute childhood leukaemia
51. Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia
52. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood
53. - lymphoblasts: Relationship of dose and duration of exposure to tumour cell viability
54. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukaemia
55. Topoisomerase IIalpha gene expression in childhood acute lymphoblastic leukaemia
56. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase
57. Biochemical and cellular pharmacology of cytosine arabinoside
58. Oral 6-mercaptopurine in childhood leukaemia: Parent drug pharmacokinetics and active metabolite concentrations
59. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
60. Thiopurine drugs in the treatment of childhood leukaemia: The influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity
61. Structure-activity relationships of VP-16 analogues
62. Exposure and schedule dependency of etoposide in neuroblastomas and leukaemia cells in vitro
63. A study of the feasibility and accuracy of pharmacologically guided etoposide dosing in children
64. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower risk B-lineage acute lymphoblastic leukaemia: A Pediatric Oncology Group trial
65. Comparison of caspase activation and sub-cellular localisation in HL-60 and K562 cells undergoing etoposide-induced apoptosis
66. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukaemic effects in vivo
67. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukaemia
68. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukaemia in children
69. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukaemic blasts from children with acute lymphoblastic leukaemia
70. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukaemia
71. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line
72. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia
73. Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukaemia
74. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukaemia: Relation with immunophenotype, in vitro drug resistance and clinical prognosis
75. Intensive consolidation chemotherapy for acute leukaemia (UKALL X pilot study)
76. Saturation of 1-β-D-arabinofuranoylcytosine 5'-triphosphate accumulation in leukaemia cells during high-dose 1-β-D-arabinofuranoylcytosine therapy
77. Extended triple intrathecal chemotherapy trial for prevention of CNS in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukaemia: A Pediatric Oncology Group Study
78. Chemotherapy in 998 unselected childhood acute lymphoblastic leukaemia patients. Results and conclusions of the multicentre trial ALL-BFM 86
79. Etoposide achieves potentially cytotoxic concentrations in the CSF of children with acute lymphoblastic leukaemia
80. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
81. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells
82. Epipodophyllotoxins in the treatment of childhood cancer
83. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukaemia
84. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamation in childhood leukaemia
85. Risk of relapse in childhood acute lymphoblastic leukaemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy
86. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections
87. Metabolic effects of thiopurine derivatives against human CCRF-CEM leukaemia cells
88. Teniposide (VM26) disposition in children with leukaemia
89. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid
90. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukaemia
91. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in culture human leukaemia cells
92. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine
93. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblast leukaemia: Results of protocol ALL VI from the Dutch childhood Leukaemia Study Group
94. Prolonged infusion of arabinosylcytosine in childhood leukaemia
95. Cytosine arabinoside transport and metabolism in acute leukaemia and T cell lymphoblastic lymphoma
96. Etoposide targets topoisomerase IIalpha and IIbeta in leukaemic cells: Isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique
97. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukaemia
98. Randomised comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukaemia
99. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines